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In a previous paper, an overview of the use of PET/CT in
the management of tuberculosis (TB) was provided and the
potential role of nitroimidazole imaging in LTBI was
considered [1]. During latent TB, dormant bacilli puta-
tively reside in a hypoxic environment of caseating lung
granulomas. Exposure of Mycobacterium tuberculosis
(Mtb) to progressive hypoxia in vitro induces a dormant
state characterized by reduced replication and metabolism
analogous to that postulated for bacilli in LTBI. In vitro,
Mtb has been shown to enter microaerophilic nonreplicat-
ing persistent (NRP) stage 1, if the dissolved oxygen
content falls below 1 %. NRP stage 1 is characterized by
thickening of the outer cell wall of Mtb and termination of
DNA synthesis. If the oxygen content further drops to
approximately 0.06 %, the bacilli enter NRP stage 2, which
is accompanied by reduced susceptibility to standard anti-
TB drugs but increased susceptibility to nitroimidazole
drugs [2]. In light of this, metronidazole, an antimicrobial
agent active against anaerobic bacteria, has been investi-
gated as a possible therapy for TB, particularly latent and
persistent TB. Metronidazole has recently been docu-
mented to be a viable option for treatment of multidrug-
resistant (MDR) TB [3].
Oxygen is an essential nutrient for mammalian cells,
because of its role as the terminal acceptor in oxidative
phosphorylation. When tissues are gradually deprived by
oxygen over time, the cells adapt to the new physiological
state of insufficient oxygen by upregulation and transcrip-
tion of certain proteins to meet metabolic demands. This
phenomenon is called hypoxia and it may occur in diseases
such as stroke, myocardial infarction with sudden vascular
occlusion or as a consequence of poor perfusion, e.g., in
diabetic limbs, arthritic joints or infections such as tuber-
culosis. Clearly, the ability to identify hypoxia has impli-
cations in a wide range of medical conditions. A clinically
suitable method for detection of hypoxia is thus essential.
In oncology, invasive probe-based methods have been
previously used including the Eppendorf needle electrode
and optical needle probes such as OxyLite. Alternatively,
immunohistochemical methods have been applied to detect
markers of hypoxia in biopsy samples taken from patients.
These markers include both exogenous systemically
delivered probes that are administered to the patient,
localizing hypoxic regions, and are detected by antibody
techniques in tissue specimens, as well as endogenous
proteins that are overexpressed under hypoxic conditions.
However, the invasiveness of these procedures as well as
their susceptibility to sampling error has encouraged the
development of image-based methods for detecting and
quantifying hypoxia [4]. PET probes have been used to
investigate hypoxia in cancer extensively. There is ade-
quate evidence to show that Mtb is exposed to hypoxia in
the granuloma in latent TB [5]. It can therefore be envis-
aged that hypoxic granuloma in TB and in anaerobic and
microaerophilic infections could be detected by PET
probes for hypoxia imaging. The heterogeneous lesions
both in active disease and subclinical disease could be
studied by combined PET/CT imaging. The CT component
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can localize the granulomas and PET can demonstrate the
presence or absence of hypoxia within these granulomas or
even outside the granulomas, where some latentMtb can be
localized.
Molecules containing nitroimidazole have emerged as the
most prevalent type ofmolecular probe for hypoxia imaging.
The mechanism for localization within cells has been thor-
oughly elucidated. Host cellular nitroreductase enzymes
reduce the NO2 group to the nitro anion radical. This rever-
sible process takes place in all cell types. In normoxic cells,
adequate oxygen is present to oxidize theNO2 radical back to
the original NO2 group. Thus, the molecule shuttles between
the NO2 and NO2 radical anion as it circulates through tis-
sues. The lack of oxygen in hypoxic tissues prevents the
radical anion from reverting back to the originalNO2, and the
radical anion is stabilized and further reduced to NHOH and
subsequently NH2. The amine NH2 group is reactive and
binds to cellular macromolecules, trapping it within the cell.
Through this process, the molecule accumulates in hypoxic
tissue [6]. Nitroimidazole-based probes are used for hypoxia
detection through a number of techniques including PET,
single-photon emission tomography (SPECT) and
immunohistochemistry.
There are currently a number of 2-nitroimidazole
compounds available. These include 18F-fluoromisonida-
zole (18F-FMISO), 18F-fluoroazomycin arabinoside (18F-
FAZA), 18F-fluoroerythronitroimidazole (18F-FETNIM),
18F-2-nitroimidazoltri- and pentafluoropropyl acetamide
(18F-EF3 and 18F-FF5), 18F-flortanidazole (18F-HX4), and
[18F] (1-(2-1-(1H-methyl) ethoxy)-methyl-2-nitroimida-
zole (18F-RP-170). These tracers have been validated for
detection of hypoxia in different cancer types. 18F-
FMISO, the prototype 2-nitroimidazole, has been exten-
sively studied, and other tracers have been developed to
address shortfalls with this tracer, such as its stability, and
slow clearance from background tissue causing modest
signal to noise ratio. 18F-FAZA and 18F-FETNIM are
more hydrophilic than 18F-MISO, thus should have better
clearance than 18F-MISO. 18F-EF3 and 18F-EF5 are rela-
tively more lipophilic than 18F-MISO but more stable and
a study of the metabolites showed the tracers were
unchanged.
Although there have been reports of hypoxia playing a
role in infectious disease, there are few studies involving
hypoxia imaging in infection. 18F-FMISO was able to
detect anaerobic odontogenic infections with a sensitivity
of 93 % and a specificity of 97 % [7]. 18F-FAZA has
been evaluated in vitro and in vivo to assess alveolar
echinococcosis (AE) infection caused by the larval from
metacestode of Echinococcus multilocularis in rodents
[8]. 18F-FAZA displayed a slightly elevated uptake in the
Echinococcus multilocularis vesicles in the in vitro
studies, but was not found useful in in vivo studies. This
appears to be the first and only study up till now, in
which 18F-FAZA has been used to evaluate infection. It is
important to note that metronidazole which is a nitroim-
idazole has not been found to be effective against alveolar
echinococcosis. Metronidazole is a prodrug that is acti-
vated under conditions of hypoxia. Metronidazole is an
effective therapy for the parasites Entamoeba histolytica
and Giardia lamblia. Both parasites are found in hypoxic
habitats. Both parasites reside in the intestinal lumen,
whereas Entamoeba histolytica is also present in absces-
ses. The hypoxic environment provides the right milieu
for activation of the nitroimidazole drug. The metacestode
of Echinococcus multilocularis is not subject to hypoxic
conditions as it is transported through blood and settles in
organs (usually the liver or brain). It is no surprise,
therefore, that metronidazole is neither used nor effective
for the treatment of alveolar echinococcosis even though
metronidazole has been shown to have different modes of
action in different parasites [9]. In the only study that has
been conducted with 18F-FAZA involving Echinococcus
multilocularis till now, the uptake was minimal and lim-
ited to the periphery of the AE lesions. In the same study,
both 18F-FDG and 18F-FLT showed good uptake, indi-
cating imaging of glycolytic and DNA proliferation of
metacestode and that probably there was not enough
hypoxia in the AE lesion to be imaged by a
nitroimidazole.
PET/CT imaging with radiolabeled nitroimidazoles
could provide a unique opportunity to non-invasively
study the hypoxic state of all granulomas within the
body. In vitro evidence supports the potential use of
hypoxia imaging in TB. Pimonidazole is a nitroimida-
zole used for immunohistochemical staining of hypoxic
tissue. The intensity of pimonidazole staining was found
to correlate directly with the number of encapsulated
living Mtb bacteria 28 days after hypoxia was induced in
an in vivo model of latent TB. This suggests that radi-
olabeled nitroimidazole PET/CT imaging may provide
information not only on the presence of hypoxia, but
also on the number of latent bacilli present in a granu-
loma [10]. The concept of imaging a microorganism
with a drug, the pathogen is susceptible to has already
been used in PET/CT imaging for several microorganism
including TB [1].
Imaging TB with radiolabeled nitroimidazole could
potentially provide answers not only for the latent stage of
TB, but may help in assessing risk of progression to
reactivation based on the number of dormant or persistent
bacilli. It may be instrumental in developing new antimi-
crobials that would need to be taken for only a short period
of time, as these drugs would target the latent phenotype
bacteria. Future research may provide new insights into the
biology of the hypoxic TB granulomas, and thereby
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increase our understanding of the role of hypoxia in the
latency and persistence stage. In the future, hypoxia
imaging may also provide a stratification approach for
individuals with LTBI and serve as an objective test in
determining individuals with LTBI who would require
treatment. Finally, hypoxia imaging may help with the
development of new vaccines targeting patients with LTBI
or persistent (MDR-TB) and may promote the development
of new TB drugs targeting LTBI which will eventually lead
to reducing the duration of current treatment. This would
increase adherence and ultimately make the goal of erad-
ication of TB by 2050 achievable.
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